Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection-Reference-Cited by-同舟云学术

Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection

Published:2024-05-05 Issue:9 Volume:12 Page:948
ISSN:2227-9032
Container-title:Healthcare
language:en
Short-container-title:Healthcare

Author:

Lugo-Trampe Angel¹²^ORCID,López-Cifuentes Daniel³,Mendoza-Pérez Paúl¹,Tafurt-Cardona Yaliana¹,Joo-Domínguez Alejandra de Jesús¹,Rios-Ibarra Clara Patricia⁴,Espinoza-Ruiz Marisol³,Chang-Rueda Consuelo³^ORCID,Rodriguez-Sanchez Iram Pablo⁵,Martinez-Fierro Margarita L.⁶^ORCID,Delgado-Enciso Iván⁷⁸^ORCID,Trujillo-Murillo Karina del Carmen¹^ORCID

Affiliation:

1. Faculty of Human Medicine, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico

2. Genodiagnóstica SA de CV, Tapachula, Chiapas 30700, Mexico

3. Faculty of Chemistry Sciences, Campus IV, Universidad Autónoma de Chiapas, Tapachula 30700, Mexico

4. Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ), Guadalajara 44270, Mexico

5. Molecular and Structural Physiology Laboratory, School of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, Mexico

6. Molecular Medicine Laboratory, Unidad de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico

7. School of Medicine, University of Colima, Colima 28040, Mexico

8. Colima Cancerology State Institute, IMSS-Bienestar, Colima 28085, Mexico

Abstract

Between 2 and 8.5% of patients who recover from COVID-19 do not develop antibodies, and the durability of IgG antibodies is under scrutiny. Therefore, the presence and persistence of IgM and IgG antibodies were evaluated in a group of patients diagnosed with SARS-CoV-2 from May to August 2020. Out of 2199 suspected COVID-19 cases, 1264 were confirmed for SARS-CoV-2 by rRT-PCR; 328 consented to participate in the study, with 220 participants followed for 9 months, including 124 men (56%) and 96 women (44%). The primary symptoms were headache, dry cough, and fever. IgG antibodies developed in 95% of patients within 4 weeks post-diagnosis, and a second evaluation at 9 months showed that 72.7% still had detectable IgG antibodies. The presence of IgM in one individual (0.45%) suggested the possibility of reinfection.

Funder

Consejo Nacional de Humanidades, Ciencia y Tecnología

Publisher

MDPI AG

Link

https://www.mdpi.com/2227-9032/12/9/948/pdf

Reference44 articles.

1. Ashour, H.M., Elkhatib, W.F., Rahman, M.M., and Elshabrawy, H.A. (2020). Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens, 9.

2. (2024, April 01). COVID-19 Cases | WHO COVID-19 Dashboard. Available online: https://data.who.int/dashboards/covid19/cases.

3. de Salud, S. (2024, April 01). Informe Semanal COVID19 2023. Available online: https://www.gob.mx/salud/documentos/informe-semanal-covid19-2023.

4. (2024, April 01). COVID-19 Tablero México. Available online: https://datos.covid-19.conacyt.mx/.

5. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses;Letko;Nat. Microbiol.,2020